Market closed

Tyra Biosciences/$TYRA

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Tyra Biosciences

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).

Ticker

$TYRA
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
Carlsbad, United States

Employees

49
Website
tyra.bio

Tyra Biosciences Metrics

BasicAdvanced
$838M
-
-$1.57
1.08
-

$838M

1.08

$27.66

$12.17

239K

29.549

29.26

1.634

1.744

-20.21%

-28.66%

2.33

2.33

-13.048

13.07%

-33.09%

What the Analysts think about Tyra Biosciences

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Tyra Biosciences stock.

Tyra Biosciences Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Tyra Biosciences Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

Tyra Biosciences News

AllArticlesVideos
Post-Election Insider Buying in These 6 Stocks Is Huge

Post-Election Insider Buying in These 6 Stocks Is Huge

24/7 Wall Street·2 months ago
Why Is Cancer-Focused Tyra Biosciences Stock Falling On Friday?

Why Is Cancer-Focused Tyra Biosciences Stock Falling On Friday?

Benzinga·3 months ago
Tyra Biosciences: Upcoming FGFR3 Inhibitor Data Is A Major Inflection Point

Tyra Biosciences: Upcoming FGFR3 Inhibitor Data Is A Major Inflection Point

Seeking Alpha·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $TYRA

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Tyra Biosciences stock?

Tyra Biosciences (TYRA) has a market cap of $838M as of January 15, 2025.

What is the P/E ratio for Tyra Biosciences stock?

The price to earnings (P/E) ratio for Tyra Biosciences (TYRA) stock is 0 as of January 15, 2025.

Does Tyra Biosciences stock pay dividends?

No, Tyra Biosciences (TYRA) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Tyra Biosciences dividend payment date?

Tyra Biosciences (TYRA) stock does not pay dividends to its shareholders.

What is the beta indicator for Tyra Biosciences?

Tyra Biosciences (TYRA) has a beta rating of 1.08. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.